このエントリーをはてなブックマークに追加
ID 31816
JaLCDOI
フルテキストURL
著者
Okita, Atsushi Department of Surgery, National Hospital Organization, Shikoku Cancer Center
Saeki, Toshiaki Department of Surgery, National Hospital Organization, Shikoku Cancer Center
Aogi, Kenjiro Department of Surgery, National Hospital Organization, Shikoku Cancer Center
Osumi, Shozo Department of Surgery, National Hospital Organization, Shikoku Cancer Center
Takashima, Shigemitsu Department of Surgery, National Hospital Organization, Shikoku Cancer Center
Okita, Riki Department of Surgery, National Hospital Organization, Shikoku Cancer Center
Taira, Naruto Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kakishita, Tomokazu Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kurita, Akira Department of Surgery, National Hospital Organization, Shikoku Cancer Center
抄録

Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule was 80mg/m2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered again. Toxicities, response rate, and time to treatment failure were assessed. All patients had been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy. There was no grade 3 or greater non-hematological toxicity. There was no complete response and 1 partial response, producing a response rate of 6.7%. Median time to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional p-glycoprotein are warranted.

キーワード
toremifene
paclitaxel
p-glycoprotein
metastatic breast cancer
Amo Type
Original Article
発行日
2009-08
出版物タイトル
Acta Medica Okayama
63巻
4号
出版者
Okayama University Medical School
開始ページ
187
終了ページ
194
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT